Jump to content

Litifilimab

From Wikipedia, the free encyclopedia
Litifilimab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetBDCA2
Identifiers
CAS Number
PubChem CID

Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti-BDCA2 monocolonal antibody.[1][2][3]

References

[edit]
  1. ^ "Litifilimab - Biogen". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Cho SK, Vazquez T, Werth VP (May 2023). "Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus". Expert Opinion on Investigational Drugs. 32 (5): 345–353. doi:10.1080/13543784.2023.2212154. PMID 37148249. S2CID 258547912.
  3. ^ Cho YM, Furie R (October 2023). "The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus". Immunotherapy. doi:10.2217/imt-2023-0086. PMID 37877249. S2CID 264448220.